In a randomized clinical trial, SLActive® implants in irradiated patients showed a success rate of 100% after 1-year
Clinical evidence shows the high predictability of SLActive® in diabetic patients. 4
In a recent preclinical study 5 , SLActive® showed significantly higher formation of new bone aggregate within eight weeks compared to the standard Straumann® SLA® surface.
1 Patients treated with dental implants after surgery and radio-chemotherapy of oral cancer. Heberer S, Kilic S, Hossamo J, Raguse J-D, Nelson K. Rehabilitation of irradiated patients with modified and conventional sandblasted, acid-etched implants: preliminary results of a split-mouth study. Clin. Oral Impl. Res. 22, 2011; 546–551. 2 C. Nack, J.-D. Raguse, A. Stricker, K. Nelson & S. Nahles. Rehabilitation of irradiated patients with chemically modified and conventional SLA implants: five-year follow-up. Journal of Oral Rehabilitation 2015 42; 57—64. 3 Nelson, K., Stricker, A., Raguse, J.-D. and Nahles, S. (2016), Rehabilitation of irradiated patients with chemically modified and conventional SLA implants: a clinical clarification. J Oral Rehabil, 43: 871–872. doi:10.1111/joor.12434. 4 Machuca G., Cabrera J.J. “A prospective, case-control clinical study of titanium-zirconium alloyw implants with hydrophilic surface in patients with Type 2 diabetes mellitus” Manuscript accepted. 5 Straumann (2016). SLActive supports enhanced bone formation in a minipig surgical GBR model with coronal circumferential defects. Unpublished data